Johnson & Johnson

6-Hour Virtual Seminar on Combination Products - Webinar - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 5:18pm

Salma Michor, PhD, MSc, MBA, CMgr, RAC is founder and CEO of Michor Consulting Schweiz GmbH, serving such clients as Johnson & Johnson, Novartis, Shire, Pfizer and Colgate Palmolive.

Key Points: 
  • Salma Michor, PhD, MSc, MBA, CMgr, RAC is founder and CEO of Michor Consulting Schweiz GmbH, serving such clients as Johnson & Johnson, Novartis, Shire, Pfizer and Colgate Palmolive.
  • Previously, Michor worked for Chiesi-Torrex, Wyeth Whitehall Export Croma Pharma GmbH.
  • She teaches regulatory affairs and clinical strategies at the University of Krems, Austria, and is an independent expert to the European Commission.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005604/en/

Award-Winning Journalist Eben Shapiro Joins Storytelling Firm SellersEaston Media

Retrieved on: 
Wednesday, August 17, 2022 - 3:09pm

SellersEaston Media announced today that it has strengthened its storytelling capabilities with the hiring of veteran writer and editor Eben Shapiro.

Key Points: 
  • SellersEaston Media announced today that it has strengthened its storytelling capabilities with the hiring of veteran writer and editor Eben Shapiro.
  • Eben shares our DNA for expert interviewing and compelling storytelling that inspires across all channels, whether in print, on video, or on stage.
  • Shapiro is joining SellersEaston after serving as Deputy Editor of TIME, where he ran daily operations.
  • SellersEaston reflects what I love best about great journalism: interviewing compelling individuals, digging, writing, and making deep connections between people and ideas, Shapiro said.

BairesDev Ranked as one of the Fastest-Growing Companies in the US by Inc. 5000

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

"BairesDev is an essential part of our client's digital transformation journeys," said Nacho de Marco, CEO, and co-founder of BairesDev.

Key Points: 
  • "BairesDev is an essential part of our client's digital transformation journeys," said Nacho de Marco, CEO, and co-founder of BairesDev.
  • Despite some challenging US and global macroeconomic trends, we're still growing at a record pace and the rest of 2022 looks even brighter.
  • The tech company has successfully executed more than 1,250 projects in over 75 industries by providing tailor-made technology solutions.
  • With 5,000+ seasoned engineers in 36 countries, BairesDev provides time zone aligned services to empower Fortune 500 companies and leading brands.

Electrolit Welcomes Christian Patiño Webb as New Chief Executive Officer

Retrieved on: 
Wednesday, August 17, 2022 - 12:04pm

CERRITOS, Calif., Aug. 17, 2022 /PRNewswire/ -- Electrolit the preferred, premium hydration beverage made from pharmaceutical quality grade ingredients - is pleased to welcome Christian Patio Webbas the company's new Chief Executive Officer.

Key Points: 
  • CERRITOS, Calif., Aug. 17, 2022 /PRNewswire/ -- Electrolit the preferred, premium hydration beverage made from pharmaceutical quality grade ingredients - is pleased to welcome Christian Patio Webbas the company's new Chief Executive Officer.
  • "It is an exciting opportunity to lead a brand with the legacy and momentum that Electrolit has and even more with the potential moving forward," said Christian Patio Webb.
  • Earning his Bachelor of Science in Industrial Engineering from Universidad Anhuac and his MBA from Duke University, Patio Webb has the educational background for this role.
  • Working at Procter & Gamble for 7 years, Patio Webb gained experience with American multinational consumer goods.

9Rooftops Welcomes Kristina Katsoulas as Senior Public Relations Manager

Retrieved on: 
Tuesday, August 16, 2022 - 3:52pm

9Rooftops recently welcomed Kristina Katsoulas as Senior Public Relations Manager.

Key Points: 
  • 9Rooftops recently welcomed Kristina Katsoulas as Senior Public Relations Manager.
  • Kristina brings over 15 years of experience to the agency, leading and providing strategic direction in the day-to-day development of public relations initiatives for several 9Rooftops clients including McLean Hospital, the Pennsylvania Turnpike Commission, and the Allegheny County Sanitation Authority.
  • Kristina has a lot of valuable public relations experience, specializing in the CPG, beauty, luxury, wellness, food, beverage, and spirits categories just to name a few, said Jon Galatis, SVP + Managing Director, Accounts at 9Rooftops.
  • For more information about 9Rooftops, visit 9Rooftops.com , LinkedIn , Instagram @9Rooftops, Facebook or Twitter @9Rooftops.

Global High Intensity Focused Ultrasound Market (2022 to 2027) - Featuring Hitachi, General Electric and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022 - 3:18pm

Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.

Key Points: 
  • Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.
  • As the COVID-19 pandemic progresses, the High-intensity focused ultrasound (HIFU) therapy industry has seen a growth drop.
  • Worldwide High-intensity Focused Ultrasound (HIFU) Therapy Market Size was US$ 269.3 Million in 2021:
    Based on modality, the High-Intensity Focused Ultrasound Therapy market is segmented into therapeutic ultrasound, hemostasis, others.
  • Major players operating in the HIFU therapy industry include Johnson & Johnson, Hitachi, Ltd, General Electric, Medtronic, Inc., Stryker, Koninklijke Philips, EDAP TMS S.A, Supersonic Imagine.

SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors

Retrieved on: 
Tuesday, August 16, 2022 - 1:30pm

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors.

Key Points: 
  • NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors.
  • We are delighted to welcome someone with the breadth and depth of industry experience as Katherine has to join our Board of Directors, stated Jane Wasman, Chair of the Board of SELLAS.
  • Additionally, she currently serves as a trustee for a not-for-profit organization, the Summit Foundation, a 501(c)(3) community foundation that fosters local philanthropy.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

Global Ophthalmology Surgical Devices Industry Assessment to 2027 with Insights on Bausch & Lomb, Topcon, and J&J Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022 - 3:57pm

The "Ophthalmology Surgical Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmology Surgical Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Ophthalmology Surgical Devices Market is anticipated to grow with a CAGR of nearly 5.5% during the forecast period.
  • Also, an increase in the investment by the key players in the ophthalmic devices sector is expected to boost the growth of the global ophthalmology surgical devices throughout the forecast period.
  • The ophthalmology surgical devices market is moderately competitive and consists of several major players.

Accumulus Synergy Announces the Appointment of Khushboo Sharma as Chief Regulatory Innovation Officer

Retrieved on: 
Monday, August 15, 2022 - 2:00pm

Khushboo Sharma joins Accumulus Synergy from BIO where she most recently served as Chief of Staff and Senior Vice President.

Key Points: 
  • Khushboo Sharma joins Accumulus Synergy from BIO where she most recently served as Chief of Staff and Senior Vice President.
  • At BIO, she oversaw the Science and Regulatory team that largely focused on major regulatory policy initiatives spanning from preclinical though post-market activities.
  • Through her work at BIO, Khushboo was at the forefront of identifying challenges and offering concrete solutions and suggestions to help build the appropriate regulatory framework.
  • Accumulus Synergy sponsors include Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, and Takeda.

6-Hour Virtual Seminar on SOP Writing, Training and Compliance in the Pharmaceutical Industry - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022 - 11:50am

The "6-Hour Virtual Seminar on SOP Writing, Training and Compliance in the Pharmaceutical Industry" webinar has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "6-Hour Virtual Seminar on SOP Writing, Training and Compliance in the Pharmaceutical Industry" webinar has been added to ResearchAndMarkets.com's offering.
  • Standard Operating Procedures (SOPs) are the basis for a large part of the day-to-day training that most pharmaceutical employees are required to perform.
  • Still, it is not widely understood the extent of the commitments we make when we write an SOP or how the writing of the SOP can have a positive or negative impact on training or job performance.
  • For example, there is an expectation that procedures describe the most critical processes for product manufacturing and will be followed consistently, with few if any deviations.